Unicycive Therapeutics (Nasdaq: UNCY) announced resubmission of its 505(b)(2) New Drug Application (NDA) to the FDA for oxylanthanum carbonate (OLC), a phosphate binder for treating hyperphosphatemia in patients with chronic kidney disease on dialysis. A new PDUFA target date is expected in 1H 2026, within 30 days of the resubmission. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at b2idigital.com/unicycive. The resubmission reflects progress by the o

199K views · 1K reactions | There’s a new Alzheimer’s drug sparking controversy in the medical field — and this is the first patient to receive it | NowThis | Facebook

FDA Circular 2016-004 Procedures on the Use of the New Application Form for License to Operate thru the FDA Electronic Portal (For All Establishments Regulated by FDA) | Food and Drug Administration Philippines

15K views · 111 reactions | Did you know that in the past 30 years...